KLRA (Kailera Therapeutics) Ending Cash Position: $130.30 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KLRA Kailera Therapeutics Inc KLRA
12 GF Score
Price $12.83
! 1 Warning Sign
View Full Analysis

What is Kailera Therapeutics Ending Cash Position?

Kailera Therapeutics KLRA -0.54% 12 Ending Cash Position is $130.30 Mil as of Jun. 2026. GuruFocus rates KLRA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Kailera Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 was $130.30 Mil.

Kailera Therapeutics's quarterly Ending Cash Position increased from Jun. 2025 ($ Mil) to Mar. 2026 ($111.83 Mil) and increased from Mar. 2026 ($111.83 Mil) to Jun. 2026 ($130.30 Mil).

Kailera Therapeutics's annual Ending Cash Position increased from . 20 ($0.00 Mil) to Dec. 2024 ($175.18 Mil) but then declined from Dec. 2024 ($175.18 Mil) to Dec. 2025 ($160.27 Mil).

Kailera Therapeutics Ending Cash Position Related Terms

Kailera Therapeutics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Kailera Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kailera Therapeutics Ending Cash Position Chart

Kailera Therapeutics Annual Data
Trend Dec24 Dec25
Ending Cash Position
175.18 160.27

Kailera Therapeutics Quarterly Data
Jun25 Mar26 Jun26
Ending Cash Position - 111.83 130.30
KLRA
12GF Score
Kailera Therapeutics Inc KLRA
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kailera Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Kailera Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=174.417+-14.15
=160.27

Kailera Therapeutics's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=111.826+18.475
=130.30

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $130.30 Mil mean?
Kailera Therapeutics (KLRA) has a Ending Cash Position of $130.30 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kailera Therapeutics and its competitors.
Is Kailera Therapeutics' Ending Cash Position too high?
Kailera Therapeutics' current Ending Cash Position is $130.30 Mil. Overall, Kailera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kailera Therapeutics' Ending Cash Position compare to VCEL and ADMA?
Kailera Therapeutics' Ending Cash Position of $130.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Kailera Therapeutics and its competitors. Kailera Therapeutics's current Ending Cash Position is $130.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kailera Therapeutics stock overvalued right now?
Kailera Therapeutics (KLRA) has a current Ending Cash Position of $130.30 Mil. The current Ending Cash Position is $130.30 Mil. Kailera Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Kailera Therapeutics (KLRA), the current Ending Cash Position is $130.30 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kailera Therapeutics Business Description

Address 180 Third Avenue, 4th Floor, Waltham, MA, USA, 02451
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
12GF Score

Get the complete analysis for KLRA

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$12.83
Price